Submission of press release on Audited Financial Results for the quarter and year ended March 31,2025.
Awaiting price reaction for this filing.
Aurobindo Pharma reported its highest-ever quarterly and annual revenue and EBITDA. Q4FY25 revenue from operations rose 10.6% year-on-year to INR 8,382 crore, while full-year FY25 revenue grew 9.4% to INR 31,724 crore. US formulations revenue jumped 13.5% to INR 4,072 crore (USD 470 million) and Europe formulations grew 17.2% to INR 2,147 crore, though Growth Markets revenue slipped 7.8% to INR 786 crore. EBITDA before R&D stood at INR 2,202 crore with a 26.3% margin, R&D spend was INR 423 crore (5% of revenue), and net profit for the quarter was INR 903 crore with an EPS of INR 15.56. The company received 5 final ANDA approvals from the USFDA in the quarter, launching 5 new products, and filed 9 new ANDAs, taking cumulative filings to 861.
Record quarterly revenue and EBITDA, strong double-digit growth in US and Europe businesses, and steady ANDA pipeline approvals are positive signals for shareholders. However, a slight dip in net profit YoY and weakness in Growth Markets may temper near-term sentiment, while the management outlook on capacity expansion and the path to USD 1 billion Europe revenue suggests continued growth momentum.